Business Wire

CA-FORESCOUT

Share
Forescout Launches Forescout Frontline to Help Organizations Tackle Ransomware and Real Time Threats

Forescout Technologies , the leader in automated cybersecurity, today announced the launch of Forescout Frontline , a new threat hunting service utilizing a team of highly-trained cybersecurity analysts to support cybersecurity teams by proactively identifying risks, enabling accelerated incident response, and maturing security posture. Forescout is offering this complimentary service for organizations that lack the internal resources and visibility to defend themselves from cybersecurity attacks, including ransomware and advanced persistent threats (APT).

“Cybersecurity attacks are on the rise. Simultaneously, cybersecurity teams are perennially understaffed and under resourced. This has created a perfect storm,” said Shawn Taylor, vice president of threat defense. “Organizations are under immense pressure to cope with the scale and speed of attacks and the havoc caused by the adversaries. Forescout is launching this new service to help organizations defend against attacks by providing a complete and holistic view of their assets.”

Many organizations use multiple security tools across multiple teams to help identify threats and risks. However, insights may be limited due to siloed views of IT, IoT, IoMT or OT assets. Typically, a variety of these asset types exist across an organization’s digital terrain and are often interconnected, which means cybersecurity risk must be identified and tackled holistically.

Delivered by Forescout Frontline analysts, the Threat Hunting and Risk Identification Service overcomes staffing resources and asset visibility challenges to uncover threats and identify risks that may otherwise remain undiscovered. Forescout Frontline will help organizations:

  • Discover, validate and prioritize a wide variety of cyber threats and vulnerabilities across all assets, including IT, IoT, IoMT and OT
  • Analyze the context and risk associated with all findings
  • Leverage the comprehensive insights to develop effective risk mitigation and remediation strategies

A State of Florida Agency, which supports several key Florida departments, engaged Forescout Frontline to understand each instance of Log4j, a zero-day vulnerability in a popular Java logging framework, across the organization’s 220 sites in 16 diverse divisions. In less than a day and a half, Forescout Frontline delivered insights into thousands of assets with vulnerabilities such as Log4j and Windows-based PrintNightmare. Additionally, hundreds of Critical CVSS-rated vulnerabilities affecting infrastructure devices such as switches and routers were found. Finally, actionable intelligence concerning critical embedded IoT TCP-IP stack-based instances such as NUCLEUS: 13 and RIPPLE 20, insecure communications, and other risks were also discovered. Leveraging this free service shrunk time to mitigation and remediation of these security gaps and improved overall security posture.

“When Log4J broke, we knew it was a critical issue, but we lacked a full picture of the risk within our extended enterprise. The [Forescout threat hunting] report was way more thorough than I expected, with in-depth information and actionable intelligence. Not just on Log4j but on other critical vulnerabilities as well, and not just in general terms but exactly where they exist in our environment.” – Information Security Manager, State of Florida Agency

Forescout Frontline levels the cybersecurity playing field by operationalizing the vulnerability research and threat intelligence produced by Forescout’s Vedere Labs and enhancing it with the Forescout Continuum Platform to provide threat hunting services across multiple dimensions. Forescout Frontline analysts include former public sector and private sector threat hunters with training in threat detection and incident response.

To learn more about Forescout Frontline, visit here , and for further insight into how a State of Florida agency benefitted from this new service, visit here.

About Forescout

Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types – IT, OT, IoT, IoMT. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets.

Managing cyber risk, together.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye